Bloodbath Signals Biotech Bubble Bursting?

Bloodbath Signals Biotech Bubble Bursting?

This episode of The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector.

In this video, health-care analysts David Williamson and Max Macaluso discuss Washington, D.C.'s impact on health-care stocks. This time, it isn't the Obamacare or the ongoing government shutdown but the threat of breaching the debt ceiling that has investors spooked for a second straight day.

Shares of the Nasdaq Biotechnology index fell again, adding another 2% decline to yesterday's sell-off while the S&P Biotech index plunged an additional 4%, far underperforming the broader market.

While the carnage wasn't as universal as yesterday's bloodbath, we still saw a a wide swath of popular biotech stocks sharply decline. During turbulent times, investors often take their money out of volatile small-cap stocks, especially ones that have seen such strong performance over the last 12 months.

Watch and find out which stocks were hit the hardest and whether the biotech bubble has burst.

More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Bloodbath Signals Biotech Bubble Bursting? originally appeared on

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Max Macaluso, Ph.D. owns shares of Sarepta Therapeutics. The Motley Fool recommends Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published